GlassScriptPhysician profile
Thomas Gee-Ming Ng
NPI 1295295418
$1,116.52
in general payments reported to CMS, 2019-2025
15 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $297.14 | 2023-2025 | Tezspire, Fasenra, Andexxa |
| Glaxosmithkline, LLC. | $171.59 | 2025 | Nucala, Trelegy Ellipta |
| Philips North America LLC | $90.43 | 2023-2025 | Vest Therapy Und, Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.92 | 2025 | Jascayd |
| Verona Pharma, INC. | $74.45 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $70.51 | 2025 | Glassia |
| Viatris Specialty LLC | $67.83 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $48.95 | 2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $41.14 | 2025 | Dupixent |
| Azurity Pharmaceuticals, INC. | $37.40 | 2025 | Alvesco |
| Electromed, INC. | $35.67 | 2025 | Smartvest |
| Lilly USA, LLC | $28.11 | 2025 | Zepbound |
| Baxter Healthcare | $25.41 | 2025 | Hillrom - Monarch Airway Clearance System |
| Insmed, INC. | $24.32 | 2025 | Brinsupri, Arikayce |
| Amgen INC. | $19.65 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.